Monoclonal IgG N‑Glycosylation Profiles for Multiple Myeloma Patients and Controls

A 2026 study by Rui Zhao profiles site-specific N-glycosylation of monoclonal immunoglobulins from serum. The dataset includes quantitative glycopeptide data from a cohort of 81 individuals (26 healthy controls, 23 IgG-MGUS patients, 32 IgG-MM patients) plus an independent validation set of 28 individuals. Longitudinal analysis covers samples from 14 newly diagnosed, 7 very good partial response, and 5 complete response multiple myeloma patients.

Use Cases

• Identify diagnostic biomarkers for multiple myeloma based on sialylated glycopeptide signatures.
• Monitor therapeutic response in multiple myeloma patients based on dynamic changes in specific glycoforms like IgG1H4N4F1S1.
• Compare glycosylation patterns across disease stages (healthy, MGUS, MM) using quantitative glycoproteomic profiles.
• Correlate specific glycoform abundance with clinical parameters mentioned in the study.

Strengths

• Includes data from a defined clinical cohort of 81 individuals plus a 28-person validation set.
• Contains longitudinal data tracking 26 samples from patients across different treatment response stages.
• Reports specific diagnostic performance metrics, such as an AUC of 0.902 for the IgG1H4N4F1S1 glycoform.

Limitations

• Row count is unknown, which may limit suitability assessment.
• Column-level documentation is absent; field semantics must be inferred after download.
• The dataset is small (44.1 KB), indicating limited scope.

Provenance

Source

Rui Zhao via figshare.

Collection Method

Integrated workflow coupling serum protein electrophoresis with ZenoTOF mass spectrometry for profiling intact N-glycopeptides from purified serum M-proteins.

Freshness

Last updated 2026-06-01 18:08:43; freshness should be verified.